Fenbendazole and Ivermectin for Head and Neck Cancer: A Case Series of 16 Patients (2026 Update)
Abstract
Background:
Head and neck cancers (HNC), predominantly squamous cell carcinomas, remain a significant global health burden with substantial morbidity and mortality, particularly in advanced or recurrent disease. Despite progress in surgery, radiotherapy, and immunotherapy, treatment resistance and toxicity continue to limit long-term outcomes. Repurposed antiparasitic agents, including ivermectin and fenbendazole, have gained attention for their potential anticancer properties based on preclinical evidence and emerging anecdotal clinical observations.
Objective:
To evaluate the biological rationale, preclinical evidence, and real-world anecdotal data supporting the use of ivermectin and fenbendazole in head and neck cancers, and to contextualize these findings within current oncologic treatment paradigms.
Methods:
A narrative synthesis was conducted integrating mechanistic studies, preclinical oncology literature, and publicly available case reports involving ivermectin and fenbendazole use in head and neck cancer patients. Reported outcomes, treatment combinations, and clinical contexts were qualitatively analyzed alongside known pharmacologic mechanisms.
Results:
Preclinical studies suggest that ivermectin and fenbendazole exert anticancer effects through multiple pathways, including microtubule disruption, inhibition of oncogenic signaling, metabolic interference, and induction of apoptosis. Aggregated anecdotal reports describe tumor regression, biomarker improvements, and occasional complete responses in head and neck cancer cases, frequently in combination with standard therapies such as chemotherapy, radiotherapy, or immunotherapy. However, these observations are heterogeneous, uncontrolled, and subject to significant confounding. (onedaymd.com)
Conclusions:
Ivermectin and fenbendazole demonstrate plausible anticancer mechanisms and encouraging anecdotal signals in head and neck cancer, but current evidence remains insufficient to establish efficacy or safety in clinical practice. Well-designed randomized controlled trials are urgently needed to determine their therapeutic role, optimal dosing, and integration into multimodal cancer care.
Introduction
Head and neck cancers (HNC) encompass a diverse group of malignancies arising from the oral cavity, pharynx, and larynx, with squamous cell carcinoma representing the predominant histological subtype. These cancers are frequently associated with established risk factors such as tobacco use, alcohol consumption, and oncogenic viral infections, particularly human papillomavirus (HPV). Despite advances in multidisciplinary management—including surgery, radiotherapy, chemotherapy, and immune checkpoint inhibitors—treatment outcomes for advanced-stage disease remain suboptimal, with high rates of recurrence, treatment-related toxicity, and functional impairment.
In parallel with ongoing therapeutic challenges, there has been growing interest in drug repurposing as a strategy to identify low-cost, widely accessible agents with anticancer potential. Among these, ivermectin and fenbendazole—traditionally used as antiparasitic agents—have emerged as candidates based on accumulating preclinical evidence. Mechanistic studies indicate that these agents may disrupt cancer cell proliferation through microtubule destabilization, inhibition of key signaling pathways, interference with tumor metabolism, and induction of apoptosis. (onedaymd.com)
Beyond laboratory findings, a growing body of anecdotal clinical reports and case series has described the use of ivermectin and fenbendazole across various cancer types, including head and neck cancers. These reports have documented outcomes ranging from disease stabilization to apparent tumor regression, often in combination with standard oncologic therapies. (onedaymd.com) However, such evidence is inherently limited by lack of control groups, heterogeneity in treatment protocols, and potential reporting bias, making causal interpretation challenging.
The increasing dissemination of these observations—particularly through digital platforms—has contributed to heightened patient interest and off-label use, underscoring the need for rigorous scientific evaluation. While repurposed drugs offer a compelling avenue for expanding therapeutic options, especially in resource-constrained settings, their integration into oncology requires careful validation through controlled clinical trials.
This article aims to critically examine the current evidence surrounding ivermectin and fenbendazole in the context of head and neck cancer, integrating mechanistic insights, preclinical data, and real-world observations to provide a balanced, evidence-informed perspective on their potential role in future cancer treatment strategies.Head and Neck Cancer Case Reports (16 cases)
.png)
Case 16 - 2026: 58 year old HONG KONG Man with Stage 4 Head and Neck SCC (squamous cell carcinoma) of Hypopharynx
Dr William Makis posted on X.com in April 2026:
IVERMECTIN and MEBENDAZOLE Testimonial - 58 year old HONG KONG Man with Stage 4 Head and Neck SCC of Hypopharynx reports after 3 months: almost complete resolution!
Ivermectin Cancer Revolution arrives in HONG KONG! How amazing!
STORY:
58 year old HONG KONG Man with Stage 4 Head and Neck SCC of Hypopharynx
In November 2025 he started:
Ivermectin, Mebendazole, Chemo
Results after 3 months: Almost complete resolution of primary H&N SCC tumor and lymph node metastases.
Once again, we see treatment synergy at work:
Ivermectin + Mebendazole + Chemo.
Case 15 - 2026: 57 year old New York woman with Stage 4 Tongue Cancer
Dr William Makis posted on X.com in January 2026:
IVERMECTIN, FENBENDAZOLE, MEBENDAZOLE, NICLOSAMIDE Testimonial - 57 year old New York woman with Stage 4 Tongue Cancer reports after 8 months: 90% of cancer GONE! World's First.
IVERMECTIN, FENBENDAZOLE, MEBENDAZOLE, NICLOSAMIDE Testimonial - 57 year old New York woman with Stage 4 Tongue Cancer reports after 8 months: 90% of cancer GONE! World's First.
This is a very special New York story.
57 year old New York woman with Stage 4 Tongue Cancer.
In May 2025 she started:
Ivermectin 1.0mg/kg/day
Mebendazole 1000mg/day
In August 2025 she added:
Fenbendazole 1000mg/day
In October 2025 she increased and added:
Fenbendazole 2000mg/day
Mebendazole 2000mg/day
Niclosamide 2000mg
Results after 8 months: 90% of cancer gone.
"The Oncologist was completely BLOWN away, as he said that 90% of her cancer has been resolved"
KEY POINTS:
This is a WORLD’S FIRST for reasons I will explain in future articles.
This case has just made history. If you know, you know.
Case 14 - 2025: 46 year old Oklahoma man with Squamous Cell Carcinoma of Base of Tongue combines it with Proton Radiation
Dr William Makis shared on X.com in October 2025:
IVERMECTIN and MEBENDAZOLE Testimonial - 63 year old Florida Man with Stage 3 SCC Tongue Cancer (HPV+) metastatic to lymph nodes has complete response after 3 months!
A success story out of FLORIDA! (soon to be backed by extensive research)
63 year old Florida Man with Stage 3 SCC Tongue Cancer (HPV+) metastatic to lymph nodes
In June 2025 he started:
Ivermectin 1.1 to 1.6mg/kg/day
Mebendazole 1000mg/day
Response after 3 months:
Complete metabolic response on PET
NAV Dx Score of 0.
Please note that he has only 1 kidney and had no side effects or lab value changes with high doses of Ivermectin and Mebendazole.
Case 13 - 2025: Head and Neck Small squamous cell Carcinoma stage 3+ (Left tonsil cancer with extension to the posterior tongue and involvement of lymph nodes on the left side of the neck)
Published in Jan 2025 on Brighter-Works Cancer Alternatives Substack:
In December of 2023, I received a life-altering diagnosis: cancer that had originated in my left tonsil and had metastasized to the back of my tongue and into the lymph nodes on the left side of my neck. Faced with the oncologists' recommendation of undergoing 37 sessions of radiation and chemotherapy, I chose to forge my own path by developing a personalized treatment protocol. I firmly believe in the potential of natural products and their ability to support our bodies in healing, but similar to pharmaceuticals, some elements of my protocol, such as Ivermectin, can also present opportunities for abuse or misuse. I cured my cancer with the protocol and my faith. But i did so using smaller doses.
Published in Feb 2025 on Brighter-Works Cancer Alternatives Substack:
When I fought my Cancer, Head and Neck Small squamous cell Carcinoma stage 3+, I used Fenben at 444mg a day. When people take this many do so on an empty stomach or with just a little food as they are not aware of the poor absorption rates for Fenbendazole. However, unlike the many people who use it I incorporated it in such a way that it increased bioavailability by up to 500% (see my notes at the end of my article). Because Fenben is not water soluble it MUST be taken the way I mention, or you lose it’s real potential. and in effect I may have taken a 444mg dose but with the increased bioavailability of my methods can increase that to a comparative 900 -1700mg dose, taken without an oil carrier. This is all about Absorption and how we can best use a simple method to increase the effectiveness of our Fenbendazole dose.
Case 12 - 2025: Stage 4 Adenoid Cystic Carcinoma (ACC), a type of salivary gland cancer
In 2017, Tim Schooley noticed a bump on his cheek.
At first, he thought it was dental-related. But after a series of referrals, a biopsy revealed a rare and slow-growing cancer: Adenoid Cystic Carcinoma (ACC), a type of salivary gland cancer.
“I was told there was a possibility that I might not be able to open my left eye again after surgery. But the operation went swimmingly.”
Tim underwent a 12-hour surgery followed by traditional radiation. The treatment successfully removed the tumor. At that point, he was cancer-free and because of the slow-growing nature of this type of cancer, doctors were hopeful it might never return…
But it did.
Scans later showed the cancer had returned this time spreading to his lungs, making it stage 4 and considered incurable.
In late 2018, scans showed that the cancer had returned this time in Tim’s lungs. Despite having six tumors, Tim still didn’t feel any symptoms.
“My oncologist said, ‘We don’t really have any great standard treatment strategy for this… but we can connect you to clinical trials.’”
Over the next few years, Tim enrolled in three clinical trials. Though it was unclear how effective they were, he believes they bought him time. Time to ask better questions. Time to explore other options.
It was during this in-between period that Tim began researching integrative strategies. An integrative oncologist handed him a study on intermittent fasting and cancer, and it clicked. He dove into books like “Tripping Over the Truth” and “Radical Remission”, learning about metabolic therapies and the terrain theory of cancer.
In early 2022, Tim sought out a repurposed drug protocol that included four medications: metformin, doxycycline, mebendazole, and atorvastatin. The overlap between metabolic disease and cancer became increasingly clear to him.
Published in July 2025 on Heal Navigator:
In 2017, Tim Schooley noticed a bump on his cheek.
At first, he thought it was dental-related. But after a series of referrals, a biopsy revealed a rare and slow-growing cancer: Adenoid Cystic Carcinoma (ACC), a type of salivary gland cancer.
“I was told there was a possibility that I might not be able to open my left eye again after surgery. But the operation went swimmingly.”
Tim underwent a 12-hour surgery followed by traditional radiation. The treatment successfully removed the tumor. At that point, he was cancer-free and because of the slow-growing nature of this type of cancer, doctors were hopeful it might never return…
But it did.
Scans later showed the cancer had returned this time spreading to his lungs, making it stage 4 and considered incurable.
In late 2018, scans showed that the cancer had returned this time in Tim’s lungs. Despite having six tumors, Tim still didn’t feel any symptoms.
“My oncologist said, ‘We don’t really have any great standard treatment strategy for this… but we can connect you to clinical trials.’”
Over the next few years, Tim enrolled in three clinical trials. Though it was unclear how effective they were, he believes they bought him time. Time to ask better questions. Time to explore other options.
It was during this in-between period that Tim began researching integrative strategies. An integrative oncologist handed him a study on intermittent fasting and cancer, and it clicked. He dove into books like “Tripping Over the Truth” and “Radical Remission”, learning about metabolic therapies and the terrain theory of cancer.
In early 2022, Tim sought out a repurposed drug protocol that included four medications: metformin, doxycycline, mebendazole, and atorvastatin. The overlap between metabolic disease and cancer became increasingly clear to him.
A turning point came in August 2022, when Tim underwent stereotactic radiation, a highly targeted therapy directed at the tumors in his lungs. This, combined with his ongoing metabolic protocol, laid the foundation for a remarkable outcome.
In May 2025, Tim’s scans came back: No evidence of disease in his lungs.
“There was just one little asterisk left, a tiny tumor that wasn’t growing. Now, it’s gone. It feels surreal.”
Even though his oncologist was cautious in tone, the scan report was clear. And Tim? He feels strong, empowered, and hopeful.
“I’ve worked myself into great functional shape. It’s strange I’ve had six tumors and never felt a symptom. Now I just feel healthy.”
Tim’s approach wasn’t a single fix. It was a layered, patient-driven journey anchored in metabolic healing, personal agency, and curiosity.
“I wish more people understood how much they can do for themselves. Don’t outsource your healing. Focus on your terrain. Stay curious.”
He also acknowledges the role conventional treatments played from the skilled surgical team to radiation and clinical trials. But for him, healing began when he stopped waiting for a silver bullet and started building a supportive internal environment.
“I used the money I earned from participating in clinical trials to pay for my repurposed meds. So really, my off-label scholarship was sponsored by Big Pharma,” he joked.
Today, Tim lives cancer-free, with a sense of peace, clarity, and gratitude. He knows the journey isn’t over, but for now, he’s thriving.
Case 11 - 2025: 46 year old Oklahoma man with Squamous Cell Carcinoma of Base of Tongue combines it with Proton Radiation
Dr William Makis shared on X/Twitter in July 2025:
IVERMECTIN, MEBENDAZOLE and FENBENDAZOLE Testimonial - 46 year old Oklahoma man with Squamous Cell Carcinoma of Base of Tongue combines it with Proton Radiation - they have never seen such a case!
Another fascinating Cancer Testimonial!
46 year old Oklahoma man with Squamous Cell Carcinoma of Base of Tongue
Patient was on:
1. Ivermectin 80mg/day
2. Mebendazole 1500mg/day
3. Fenbendazole 1000mg/day
From the patient:
"let me tell you my base of tongue and neck tumors have shrunk to almost nothing"
"I began Proton Radiation Therapy"
"My tolerance of the treatments has been something of a buzz among the Drs and caregivers.
I am 21 of 35 treatments in and I can still eat and speak fine, I can even still lead the singing at one of our weekly church services! I have no pain!
Minimum skin burn, like a slight sun burn. No thick saliva and no mucositis. Many of the people I have met since we started were in really bad shape by this point and several had to delay or quit treatment due to mucositis and swallowing difficulties"
Despite the chemo and 1500mg Mebendazole, 1000mg Fenbendazole and 80mg Ivermectin daily, my liver numbers have been excellent"
Case 10 - 2025: 67 year old woman from Zimbabwe with Stage 4 H&N SCC of Oropharynx
Dr William Makis shared on X/Twitter in May 2025:
IVERMECTIN and MEBENDAZOLE Testimonial - 67 year old woman from Zimbabwe with Stage 4 H&N SCC of Oropharynx has excellent response after less than 3 months!
I have patients from Australia to Zimbabwe.
I'm going to go deep with this success story.
STORY:
67 year old woman from Zimbabwe was diagnosed with H&N Squamous Cell Carcinoma of the back of the tongue in August 2022. She had chemo/rad.
May 2023 to Nov.2023 declared cancer free, then found to have liver mets and was declared Stage 4.
Dec.2023 to Nov.2024 was on Keytruda with good response.
Nov.2024 she failed Keytruda and developed new liver and bone metastases.
Reached out to me in late January 2025.
In February 2025 we started:
Ivermectin 1mg/kg/day
Mebendazole 1000mg/day
RESULTS on PET/CT after less than 3 months:
Liver:
“Previously visualized metastatic deposits have decreased in size, quantity and avidity”
Pelvic Lymph nodes:
Left paraaortic 2.1x1.3cm SUV 7.6 to 1.6x1.1cm SUV 2.1
(46% volume shrinkage)
Right common iliac: 1.2x1.1cm to 0.6x0.4mm
(93% volume shrinkage)
Bone lesions:
Manubrium SUV 11.5 to 1.7
L2 vertebral body SUV 3.5 to 2.6
Left Sacrum SUV 5.6 to 2.0
This success was a combination of:
Keytruda + Carboplatin + Paclitaxel + Xgeva + Ivermectin + Mebendazole.
Summary:
Dec.2023 to Nov.2024: Patient on cutting edge cancer drugs developed liver and bone metastases.
Feb.2025 to May 2025: Patient added Ivermectin & Mebendazole to new chemo/immuno and all metastases are shrinking and decreasing in metabolic activity. Liver, bone and lymph node metastases.
LESSON:
Patients often come to me when they’re at Stage 4 and progressing on the best cancer drugs modern Oncology has to offer.
I am asked to clean up Modern Oncology's failures.
Imagine if this patient had Ivermectin and Mebendazole at initial diagnosis.
She may have never progressed to stage 4.
And Big Pharma would have missed out on $100,000s in profit. This is how it works.
Let’s say I can go back in time and re-do history.
My Revision: Patient is diagnosed with tongue cancer in Aug.2022, is put on Chemo/Rad/ Ivermectin/Mebendazole, declared cancer free in May 2023 and stays cancer free.
But where is the profit in that?
Reality of Modern Oncology:
Patient is diagnosed with tongue cancer in Aug.2022, is put on chemo/rad, doctors mock Ivermectin & Mebendazole, declared cancer free May 2023, becomes Stage 4 Nov.2023 with liver mets and eventually spreads to the bones, and she spends 1.5 years battling an uphill battle with Stage 4 Cancer, while big pharma rakes in $100,000s of profit on chemo and immunotherapy.
This IS Modern Oncology.
No one knows how bad it is until they experience it.
Now imagine how low IQ someone has to be to attack me for trying to help these patients.
Not only does Modern Oncology not solve the problem at initial diagnosis, but vast majority of patients see their cancer return within 1-2 years.
This is where Modern Oncology really makes their money, once the patient is Stage 4 and on the endless treadmill of chemo and immunotherapy that allows Big pharma to make $100,000s until the patient dies.
These are the messes I am asked to clean up.
This is why I am so confident with my approach with repurposed drugs: Ivermectin, Fenbendazole, Mebendazole.
Because I know how weak Modern Oncology is.
How utterly abysmal their success rates.
I do what they can't even dream of.
From the patient:
"As a matter of interest, her oncologist was blown away with her recent scan results and I told her about you and that she has been on a repurposed medicine protocol from you."
"Her Oncologist was blown away".
Case 9: 62-year-old man with Head and Neck Squamous Cell Carcinoma of Tonsil (HPV+) with Lung Metastases
Dr William Makis shared on X/Twitter in May 2025:
IVERMECTIN and MEBENDAZOLE Testimonial - 62 year old man with Head and Neck Squamous Cell Carcinoma of Tonsil (HPV+) progressing with Lung Metastases - Cancer Free after 2.5 months!
Sounds unbelievable, doesn't it?
Stage 4 to Cancer free in such a short time...
STORY:
62 year old man diagnosed with HPV Head and Neck Squamous Cell Carcinoma of Tonsil in August 2024
Treated with 5 rounds of chemo and 37 rounds of radiation in late 2024.
Was told cancer had spread to lungs in Dec.2024.
Reached out to me in January, 2025.
We started:
Ivermectin 1mg/kg/day
Mebendazole 1000mg/day
Oncologist put him on: Paclitaxel, Carboplatin, Pembrolizumab
RESULTS (after 2.5 months):
Negative NavDx Test Result
CT: "Substantial response to treatment with near complete resolution of pulmonary metastatic disease. No new suspicious pulmonary nodule"
From the patient:
"I had a scan on Dec.30 and it showed the cancer had moved to my lungs and I had numerous nodules in both lungs"
"Heard about you and reached out in January to you. As soon as I received your protocol I began following your regimen"
"The good news is the scan of my lungs taken March 30 and the NavDx Blood test drawn on April 3 both reflect I am cancer free"
I run the world's largest Ivermectin Cancer Clinic.
Yes, the results can be this dramatic. This quickly.
Here is the part that most people miss.
This patient developed Stage 4 metastatic disease to the lungs after doing 5 rounds of chemo and 37 radiation treatments.
In other words, this patient was at an earlier stage, went to get the best treatment modern Oncology had to offer, and ended up with Stage 4 Cancer spread shortly after.
I see this all the time.
Mainstream Oncology is an absolute disaster. They don't cure anything. The treatments have no long term durability. No staying power. The cancer comes back.
Oncology needs a complete overhaul, but until then - we save lives with repurposed drugs: Ivermectin, Fenbendazole, Mebendazole and more...Mainstream Oncology has no idea what's coming and they're NOT ready for it....
Case 8: Head and Neck Squamous Cell Carcinoma
Dr William Makis shared on X/Twitter in March 2025:
IVERMECTIN Paste and FENBENDAZOLE Testimonial - Man with Head and Neck Squamous Cell Carcinoma gets to "No active disease".
This is a very short testimonial and sometimes success stories are like that. Short and sweet.
"My husband was diagnosed in 2021 with squamous cell cancer in his neck! He had a mass surrounding his carotid artery!
"My husband was diagnosed in 2021 with squamous cell cancer in his neck! He had a mass surrounding his carotid artery!
I am working on many Head and Neck squamous cell carcinoma cases in my Ivermectin Cancer Clinic.
There is evidence that H&N SCC responds to Mebendazole as well as Fenbendazole, although there is more published research on H&N SCC and Mebendazole.
There is evidence that H&N SCC responds to Mebendazole as well as Fenbendazole, although there is more published research on H&N SCC and Mebendazole.
2017 Zhang et al - Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)
"Our results are the first to demonstrate that MBZ may exert its anticancer activity by inhibiting proliferation while promoting differentiation of certain HNSCC cancer cells. It's conceivable the anthelmintic drug MBZ can be repurposed as a safe and effective agent used in combination with other frontline chemotherapy drugs such as cisplatin in HNSCC treatment."
2024 Zhang et al - Synergistic inhibition of proliferation and induction of apoptosis in oral tongue squamous cell carcinoma by mebendazole and paclitaxel via PI3K/AKT pathway mitigation.
"Both MBZ and paclitaxel treatments inhibited of cell proliferation and microtubule formation by reducing the PI3K/AKT pathway in CAL-27 and UM-SCC-1 cells, with the combination demonstrating synergistic effects. Our study suggests MBZ and paclitaxel as potential agents for the treatment of OTSCC."
Case 7: Salivary Gland Cancer (January 2025)
Shared on a Facebook Private Group (January 2025):
"I was diagnosed with stage 4 salivary gland cancer in April 2023. Had surgery and got most removed then did a very light chemo and 30 rounds of radiation. In August of 2023 my scans came back clean. We thought I was all done! Around March I had follow up scans done and now I have tumors on my spine, tailbone, liver, lung and pelvis. I've been on the ivermectin, fenbendazole protocol for a few months now. I'm from Kansas city and they aren't really familiar with my type of cancer...it's pretty rare. We came to MD ANDERSON Sunday to see if there is more they can do for me. I had scans done today but no results as of yet. The doctor has some ideas on what he wants to do. He was amazing, wish I could take him home with me! Anyway, that's my story in a nutshell and praying the doctors , protocol I'm doing and the grace of God, my Lord and Savior will help prolong my life cause I'm definitely not ready to go yet! Thank you for letting me share....God bless all of you".
Case 6: Tongue Cancer
Dr William Makis shared a case report on X-Twitter (Dec 2024):
IVERMECTIN & FENBENDAZOLE & Topical Ivermectin Testimonial - 70s year old US patient with Squamous Cell Carcinoma of Tongue seeing improvement - mainstream doctors coming on board!
I have a 70s year old US patient with a bad case of tongue cancer (squamous cell carcinoma)
Mainstream Oncology has offered to resect her tongue.
We started a high dose Ivermectin and Fenbendazole Protocol with one extra feature: topical Ivermectin cream applied twice a day.
- Ivermectin 1mg/kg/day
- Fenbendazole 888mg/day
- Topical Ivermectin applied to tongue lesion twice a day
One of her physicians contacted me:
"started on your protocol for a tongue neoplasm...She's noticed significant improvement in tumor size of the last few months...we would be in contact throughout treatment...thanks for all that you're doing!"
Case 5: 71 year old Canadian man with aggressive Stage 4 Oropharynx cancer (February 2025)
IVERMECTIN & FENBENDAZOLE Testimonial - 71 year old Canadian man with aggressive Stage 4 Oropharynx cancer sees hope and dramatic tumor shrinkage.
This patient was really not doing well on conventional radiation and chemotherapy, until he came to me...
71 year old Canadian man with aggressive Stage 4 Oropharynx cancer, progressing with lung metastases and not doing well with conventional treatments.
His Canadian oncologists couldn't get the cancer under control.
TREATMENT:
From October 2024 we started:
Ivermectin 40 to 80mg a day (he struggled but really tried to get the dose up)
Fenbendazole 1000mg a day, 6 days a week A few weeks later oncologists started: Keytruda RESULTS: CT Jan.20, 2025:
“On palliative systemic therapy”
A bit over 3 months on Ivermectin 40-80mg and Fenbendazole 1000mg 6 times a week.
Oropharynx primary tumor down from 4.0cm to 3.2cm. Right parotid mass shrunk 71% from 5.8cm to 1.7cm !! Laryngeal soft tissue mass is GONE. Cervical adenopathy shrunk 31% from 1.6cm to 1.1cm. !!
Not bad for 3 months of repurposed drugs in combination with palliative KEYTRUDA.
Case 4: Advanced Epiglottis Cancer (Throat cancer)
Dr William Makis shared on X/Twitter in November 2024:
IVERMECTIN and FENBENDAZOLE - Testimonial in a patient with Advanced Epiglottis Cancer (who was offered no treatment options)
Epiglottis Cancer is a type of Head and Neck Cancer that is difficult to treat surgically or otherwise.
"One year ago I had the death sentence"
“Surgeons offered no hope, no options”
"I heard about Ivermectin...Fenbendazole"
“I am alive & in gratitude to you and your....”
Case 3: Head & Neck Squamous Cell Cancer (Sep 2024)
According to Dr William Makis (X/Twitter):
IVERMECTIN & FENBEDAZOLE Head & Neck SCC Cancer testimonial
IVERMECTIN & FENBEDAZOLE Head & Neck SCC Cancer testimonial
For those who proceed with conventional chemotherapy or radiation therapy - you should know that you will get much better results combining with Ivermectin & Fenben. The results will often surprise the Oncologist!
Case 2: Oral cancer (Squamous cell carcinoma), February 2023
Condition: Oral cancer (Squamous cell carcinoma)
I was diagnosed 11/2/2022 with oral cancer on base of lower gums and on 11/5/2022, I start taking:
– Merck brand fenbendazole liquid goat dewormer 3ml a day (also equal 1/2 teaspoon) for 5 days a week.
– Doctor’s best brand: curcumin phytosome 500mg for 7 days a week.
– Now brand: ginger root extract 250mg for 7 days a week.
Went to my ENT doctor and he examined and scheduled surgery for 1/27 2023, (still taking fenben all the time) after excision of skin lesion it was sent to pathologist, the result came back – no cancer!!!
Which of the protocol components did you use? Fenbendazole, Curcumin, Other.
Other supplements used? Curcumin phytosome 500mg— ginger root extract 250mg.
Which conventional treatments did you do? Surgery.
Source: Heal Navigator
Case 1: Throat Cancer (HPV Squamous Cell Carcinoma) (December, 2021)
I never knew that the day would surface for me to find out that I got diagnosed with cancer. My life turned upside down in seconds that day and ever since I have been doing research upon research – reading and gathering all the information I could get on the prognosis of my cancer and the treatments that are out there to help fight what is called HPV Squamous Cell Carcinoma (throat cancer).
I ended up taking fenbendazole (dose of 2,000 mg) after a consultation with a holistic doctor who examined it with added supplements to the fenben protocol the doctor has put me on.
My tumor shrunk 1 cm in one month from using fenbendazole which was also before I had to start with several radiation treatments and doses of cisplatin chemotherapy to come. As the radiation and chemo journey started for me, I could not tolerate what it was doing to my body any more and decided to stop with it completely and just commit to my health and take fenbendazole along with the individualized supplements suggested for me to use. This took not just a lot of commitment but a lot of faith in the matter!
A few months past and near to the end of 2021, I received my follow up PET scan with the greatest news ever – I am completely cancer free – and still today! With results of significant response to the treatment.
Without saying a word to anyone out there, I pursued this journey and with experience I can say that fenbendazole can definitely cure cancer!
Source: Heal Navigator
Discussion
This analysis highlights both the promise and the limitations of repurposed antiparasitic agents—particularly ivermectin and fenbendazole—in the context of head and neck cancers (HNC). The biological plausibility underpinning these agents is supported by a growing body of preclinical literature demonstrating multi-targeted anticancer effects. These include disruption of microtubule dynamics, inhibition of oncogenic signaling pathways (e.g., Wnt/β-catenin, PI3K/Akt), modulation of tumor metabolism, and induction of apoptosis. Such mechanisms are especially relevant in HNC, where molecular heterogeneity and adaptive resistance frequently undermine single-target therapies.
A key strength of ivermectin and fenbendazole lies in their potential polypharmacology—the ability to act across multiple cancer hallmarks simultaneously. This contrasts with many conventional targeted therapies, which often lose efficacy due to pathway redundancy and tumor evolution. In theory, these agents may complement existing modalities such as chemotherapy, radiotherapy, and immunotherapy by enhancing tumor sensitivity or overcoming resistance mechanisms. For example, microtubule disruption may synergize with taxane-based chemotherapy, while metabolic interference could augment the efficacy of immune checkpoint inhibitors by altering the tumor microenvironment.
However, the current clinical evidence base remains insufficient and methodologically limited. The majority of human data derives from anecdotal case reports, self-reported patient experiences, and small, uncontrolled case series. While some reports describe striking outcomes—including tumor regression and prolonged survival—these findings must be interpreted with caution due to several critical limitations:
Selection and reporting bias: Positive outcomes are more likely to be shared publicly than negative or null results.
Confounding variables: Many patients use these agents alongside standard therapies, supplements, or lifestyle interventions, making attribution difficult.
Heterogeneity in dosing and protocols: There is no standardized regimen, leading to wide variability in exposure and outcomes.
Lack of pharmacokinetic and pharmacodynamic data in oncology settings: Optimal dosing, tissue penetration, and therapeutic windows remain unclear.
Safety considerations also warrant careful attention. While ivermectin is generally well tolerated at approved doses for parasitic infections, and fenbendazole has a favorable safety profile in veterinary use, their long-term use, high-dose regimens, and combination with other anticancer therapies have not been rigorously evaluated in humans with cancer. Potential risks include drug-drug interactions, hepatotoxicity, and unforeseen cumulative toxicities, particularly in patients undergoing intensive oncologic treatment.
From a translational perspective, the gap between preclinical promise and clinical validation represents the central challenge. Bridging this gap will require well-designed prospective studies, including dose-escalation trials, biomarker-driven patient selection, and randomized controlled trials comparing repurposed drug combinations with standard-of-care treatments. Additionally, mechanistic studies in human tumor samples and tumor microenvironment models are needed to confirm whether the pathways observed in vitro are clinically relevant in HNC.
Importantly, the rising interest in ivermectin and fenbendazole reflects a broader shift toward patient-driven innovation and decentralized data generation. While this trend can accelerate hypothesis generation, it also underscores the need for rigorous scientific frameworks to distinguish signal from noise. Integrating real-world evidence with formal clinical research may offer a pragmatic pathway forward, particularly in areas where traditional drug development is slow or underfunded.
2026 JAMA Oncology Update
- First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial (JAMA Oncology 2026)
Conclusion
Ivermectin and fenbendazole represent intriguing candidates in the evolving landscape of drug repurposing for head and neck cancers. Their multi-targeted mechanisms, low cost, and widespread availability make them attractive from both a biological and public health perspective. Preclinical data and anecdotal clinical observations provide early signals of potential anticancer activity, particularly when used in combination with established therapies.However, the current evidence remains insufficient to support routine clinical use. The absence of controlled trials, standardized dosing protocols, and robust safety data limits the ability to draw definitive conclusions regarding efficacy and risk. As such, these agents should be considered investigational within the oncology setting.
Future research should prioritize rigorous clinical validation, including randomized controlled trials and biomarker-guided strategies, to determine whether ivermectin and fenbendazole can be safely and effectively integrated into multimodal cancer care. Until such data are available, clinicians and patients should approach their use with caution, ensuring that decisions are guided by evidence, clinical judgment, and informed consent.
In the broader context, the exploration of these agents underscores the importance of innovative, multi-targeted approaches to cancer treatment—particularly in complex and treatment-resistant malignancies such as head and neck cancers. With careful scientific validation, repurposed drugs may yet play a meaningful role in expanding the therapeutic arsenal against cancer.
.png)
.png)
Comments
Post a Comment